Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of Indapamide in rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 2, 2012, Pages 208-220

  Yan, Fang ^a   Hu, Ying ^a   Di, Bin ^a,b   He, Ping Lei ^a   Sun, Guibin ^c  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Chia Tai Tianqing Pharmaceutical Group CO Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; ALPHA NAPHTHOFLAVONE; ANTIHYPERTENSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; FELODIPINE; INDAPAMIDE; IRBESARTAN; KETOCONAZOLE; NIFEDIPINE; NITRENDIPINE; PUERARIN; QUINIDINE; SULFAPHENAZOLE; TELMISARTAN; TICLOPIDINE; VALSARTAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84863285484     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3sk5v     Document Type: Article

References (34)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee, The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA, 2003; 289:2560-2572.
2. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, Leeuw De PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A, Thomas SM. Preterax in Albuminuria Regression (PREMIER) Study Group, Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension, 2003; 41:1063-1071.
3. Huang SS, Wu TC, Lin SJ, Chen JW. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J, 2009; 73:2282-2287.
4. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007; 370:829-840.
5. Graham MJ, Lake BG. Induction of drug metabolism: species differences and toxicological relevance. Toxicology, 2008; 254:184-191.
6. Caruso FS, Szabadi RR, Vukovich RA. Pharmacokinetics and clinical pharmacology of indapamide. Am Heart J, 1983; 106:212-220.
7. Albu F, Georgiţǎ C, David V, Medvedovici A. Liquid chromatography-electrospray tandem mass spectrometry method for determination of indapamide in serum for single/multiple dose bioequivalence studies of sustained release formulations. J Chromatogr B Analyt Technol Biomed Life Sci, 2005; 816: 35-40.
8. Zhang JL, Qin YW, Zheng X, Qiu JL, Zhao XX, Zou DJ. Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients. Blood Press, 2010; 19:110-118.
9. Ohashi N, Minemura S, Togawa A, Ohyama K. A case of hypokalemia-induced fatal arrhythmia caused by indapamide in an anorexic elderly patient. Clin Exp Nephrol, 2011; [Epub ahead of print].
10. ADVANCE Echocardiography Substudy Investigators and the ADVANCE Collaborative Group. Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE echocardiography substudy. J Hypertens, 2011; 29:1439-1447.
11. Leeuw de PW. Combination perindopril/indapamide for the treatment of hypertension: A review. Expert Opin Pharmacother, 2011 [Epub ahead of print]
12. Chen H, Fu LH. Effect on left ventricular hypertrophy and heart function, in treating essential hypertension with felodipine combination indapamide vs combination diuretic. Chin J New Drugs Clin Rem, 2001; 20:267-270.
13. Wang W, Xiao Q. Comparison of the effect of indapamide and nifedipine on elderly patients with hyertention. Clin J Med Officer, 2002; 30:21-23.
14. Song JL, Cheng GC, Pang WY. The experience of low-dose of nitrendipine and indapamide combined application. Chin J Med, 1998; 83:394-396.
15. Zhou GB, Sun KY, Li JC, Chen YD, Qian Z. The effect of combined telmisartan with indapamide sustained release on pulse pressure and morning blood pressure surge in older essential hypertensive patients. Chin J Hypertens, 2009; 17:406-409.
16. Kang AN. Irbesartan plus idapamide for hypertension. J Clin Exp Med, 2007; 6: 49-50.
17. Xie QY, Wang YJ, Sun ZL, Yang TL. Effects of valsartan and indapamide on plasma cytokines in essential hypertension. J Cent South Univ (Med Sci), 2006; 31:629-634.
18. Liang G, He QL, Liu JW. The effect of combined puerarin with indapamide on pulmonary heart failure. Guangdong Med J, 2005; 26:705-706.
19. Hunt BA, Self TH, Lalonde RL, Bottorff MB. Calcium channel blockers as inhibitors of drug metabolism. Chest, 1989; 96:393-399.
20. Kirch W, Kleinbloesem CH, Belz GG. Drug interactions with calcium antagonists. Pharmacol Ther, 1990; 45:109-136.
21. Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos, 1999; 27:288-296.
22. Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P, Gasparo De M. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica, 1997; 27:59-71.
23. Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II antagonist, in human liver microsomes. Xenobiotica, 2005; 35:589-602.
24. Wienen W, Entzeroth M, Meel van JCA, Stangier J, Busch U, Ebner T, Schmid J, Lehmann H, Matzek K, Kempthorne-Rawson J, Gladigau V, Hauel NH. A review on telmisartan: a novel, longacting angiotensin II-receptor antagonist. Cardiovasc Drug Rev, 2000; 18:127-156.
25. Guerra MC, Speroni E, Broccoli M, Cangini M, Pasini P, Minghett A, Crespi-Perellino N, Mirasoli M, Cantelli-Forti G, Paolini M. Comparison between chinese medical herb Pueraria lobata crude extract and its main isoflavone puerarin antioxidant properties and effects on rat liver CYP-catalysed drug metabolism. Life Sci, 2000; 67:2997-3006.
26. Wójcikowski J, Daniel WA. Influence of antidepressant drugs on chlorpromazine metabolism in human liver--an in vitro study. Pharmacol Rep, 2010; 62:1062-1069.
27. Hasegawa T, Hara K, Kenmochi T, Hata S. In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in human liver microsomes. Drug Metab Dispos, 1994; 22:916-921.
28. Liu YT, Hao K, Liu XQ, Wang GJ. Metabolism and metabolic inhibition of gambogic acid in human liver microsomes. Acta Pharmacol Sin, 2006; 27:1253-1258.
29. Chung HJ, Choi YH, Kim SH, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats. J Pharm Pharmacol, 2006; 58:449-457.
30. Jiang Y, Kuo CL, Pernecky SJ, Piper WN. The detection of cytochrome P450 2E1 and its catalytic activity in rat testis. Biochem Biophys Res Commun, 1998; 246:578-583.
31. Yu L, Waxman DJ. Role of cytochrome P450 in oxazaphosphorine metabolism. Drug Metab Dispos, 1996; 24:1254-1262.
32. Ponnusankar S, Pandit S, Venkatesh M, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibition assay for standardized extract of Terminalia chebula Retz. Phytother Res, 2011; 25:151-154.
33. Jain DS, Subbaiah G, Sanyal M, Pande UC, Shrivastav P. Liquid chromatography-tandem mass spectrometry validated method for the estimation of indapamide in human whole blood. J Chromatogr B Analyt Technol Biomed Life Sci, 2006; 834:149-154.
34. Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS. Dehydrogenation of the Indoline-Containing Drug 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbe nzamide (Indapamide) by CYP3A4: Correlation with in Silico Predictions. Drug Meta and Dispos, 2009; 37:672-684.